Cargando…

To screen or not to screen? Celiac antibodies in liver diseases

Celiac disease (CD) is a systemic immune-mediated disorder triggered by dietary gluten in genetically predisposed individuals. The typical symptoms are anemia, diarrhea, fatigue, weight loss, and abdominal pain. CD has been reported in patients with primary sclerosing cholangitis, primary biliary ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Narciso-Schiavon, Janaína Luz, Schiavon, Leonardo Lucca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296194/
https://www.ncbi.nlm.nih.gov/pubmed/28223722
http://dx.doi.org/10.3748/wjg.v23.i5.776
_version_ 1782505566912905216
author Narciso-Schiavon, Janaína Luz
Schiavon, Leonardo Lucca
author_facet Narciso-Schiavon, Janaína Luz
Schiavon, Leonardo Lucca
author_sort Narciso-Schiavon, Janaína Luz
collection PubMed
description Celiac disease (CD) is a systemic immune-mediated disorder triggered by dietary gluten in genetically predisposed individuals. The typical symptoms are anemia, diarrhea, fatigue, weight loss, and abdominal pain. CD has been reported in patients with primary sclerosing cholangitis, primary biliary cholangitis, autoimmune hepatitis, aminotransferase elevations, nonalcoholic fatty liver disease, hepatitis B, hepatitis C, portal hypertension and liver cirrhosis. We evaluate recommendations for active screening for CD in patients with liver diseases, and the effect of a gluten-free diet in these different settings. Active screening for CD is recommended in patients with liver diseases, particularly in those with autoimmune disorders, steatosis in the absence of metabolic syndrome, noncirrhotic intrahepatic portal hypertension, cryptogenic cirrhosis, and in the context of liver transplantation. In hepatitis C, diagnosis of CD can be important as a relative contraindication to interferon use. Gluten-free diet ameliorates the symptoms associated with CD; however, the associated liver disease may improve, remain the same, or progress.
format Online
Article
Text
id pubmed-5296194
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-52961942017-02-21 To screen or not to screen? Celiac antibodies in liver diseases Narciso-Schiavon, Janaína Luz Schiavon, Leonardo Lucca World J Gastroenterol Review Celiac disease (CD) is a systemic immune-mediated disorder triggered by dietary gluten in genetically predisposed individuals. The typical symptoms are anemia, diarrhea, fatigue, weight loss, and abdominal pain. CD has been reported in patients with primary sclerosing cholangitis, primary biliary cholangitis, autoimmune hepatitis, aminotransferase elevations, nonalcoholic fatty liver disease, hepatitis B, hepatitis C, portal hypertension and liver cirrhosis. We evaluate recommendations for active screening for CD in patients with liver diseases, and the effect of a gluten-free diet in these different settings. Active screening for CD is recommended in patients with liver diseases, particularly in those with autoimmune disorders, steatosis in the absence of metabolic syndrome, noncirrhotic intrahepatic portal hypertension, cryptogenic cirrhosis, and in the context of liver transplantation. In hepatitis C, diagnosis of CD can be important as a relative contraindication to interferon use. Gluten-free diet ameliorates the symptoms associated with CD; however, the associated liver disease may improve, remain the same, or progress. Baishideng Publishing Group Inc 2017-02-07 2017-02-07 /pmc/articles/PMC5296194/ /pubmed/28223722 http://dx.doi.org/10.3748/wjg.v23.i5.776 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Narciso-Schiavon, Janaína Luz
Schiavon, Leonardo Lucca
To screen or not to screen? Celiac antibodies in liver diseases
title To screen or not to screen? Celiac antibodies in liver diseases
title_full To screen or not to screen? Celiac antibodies in liver diseases
title_fullStr To screen or not to screen? Celiac antibodies in liver diseases
title_full_unstemmed To screen or not to screen? Celiac antibodies in liver diseases
title_short To screen or not to screen? Celiac antibodies in liver diseases
title_sort to screen or not to screen? celiac antibodies in liver diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296194/
https://www.ncbi.nlm.nih.gov/pubmed/28223722
http://dx.doi.org/10.3748/wjg.v23.i5.776
work_keys_str_mv AT narcisoschiavonjanainaluz toscreenornottoscreenceliacantibodiesinliverdiseases
AT schiavonleonardolucca toscreenornottoscreenceliacantibodiesinliverdiseases